Open | $11.480 |
Close | $10.120 |
Volume / Avg. | 924.870K / 728.197K |
Day Range | 9.990 - 11.480 |
52 Wk Range | 2.250 - 13.700 |
Market Cap | $625.545M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 6.41% |
Days to Cover | 5.08 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Fulcrum Therapeutics (NASDAQ: FULC) through any online brokerage.
Other companies in Fulcrum Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE), Phibro Animal Health (NASDAQ:PAHC) and Tarsus Pharmaceuticals (NASDAQ:TARS).
The latest price target for Fulcrum Therapeutics (NASDAQ: FULC) was reported by RBC Capital on Wednesday, March 13, 2024. The analyst firm set a price target for 14.00 expecting FULC to rise to within 12 months (a possible 38.61% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Fulcrum Therapeutics (NASDAQ: FULC) is $10.1 last updated March 18, 2024 at 7:57 PM EDT.
There are no upcoming dividends for Fulcrum Therapeutics.
Fulcrum Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Fulcrum Therapeutics.
Fulcrum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.